Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with a great unmet medical need. The company is headquartered in Lexington, Massachusetts. Show more

1050 WALTHAM STREET, LEXINGTON, MA, UNITED STATES, 02421, Lexington, MA, 02421, USA

BIOTECHNOLOGY
HEALTHCARE

Market Cap

218.7M

52 Wk Range

$9.69 - $22.55

Previous Close

$10.95

Open

$10.96

Volume

157,507

Day Range

$10.80 - $11.09

Enterprise Value

-24.77M

Cash

257.6M

Avg Qtr Burn

-20.42M

Insider Ownership

3.96%

Institutional Own.

95.32%

Qtr Updated

06/30/26


Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
KER-050 (elritercept) Details
Transfusion-dependent lower-risk MDS

Phase 3

Data readout

KER-050 (elritercept) Details
Blood cancer, Cystic fibrosis, Lung disease, Myelofibrosis, Cancer

Phase 3

Initiation

KER-065 Details
Duchenne muscular dystrophy

Phase 2

Data readout

Phase 2

Initiation

Phase 2

Initiation

Phase 1

Update

KER-012 (cibotercept) Details
Pulmonary hypertension, Cardiovascular disease

Failed

Discontinued

KER-047 (ALK2 inhibitor) Details
Myelodysplastic syndrome, Myelofibrosis

Failed

Discontinued

KER-047 (ALK2 inhibitor) Details
Fibrodysplasia ossificans progressiva, Anemia

Failed

Discontinued